Trial Profile
A phase I/II study of Erlotinib/Carboplatin/Pemetrexed/Bevacizumab in chemotherapy-naive patients with EGFR mutation positive advanced non-squamous non-small-cell lung cancer
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 12 May 2016
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Bevacizumab; Carboplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 14 Mar 2014 New trial record